---
search:
  boost: 3
---

# Other Agents

This is a subcategory of Respiratory Agents.

## Decision Tree

- [Respiratory - Other Agents - NP Criteria - Daliresp (BvG), roflumilas](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMDJWRURRM0Y3VjFBOFlPUllQRFVSNzhEWiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred | Generic Name | Quantity | Time (Days) |
| :-------- | :----------- | :------: | :---------: |
|           |              |          |             |

### Non-Preferred

| Non-Preferred              | Generic Name | Quantity | Time (Days) |
| :------------------------- | :----------- | :------: | :---------: |
| Roflumilast                |              |          |             |

## Authorizations

**Length of Authorizations**: Initial: 90 days; Subsequent: 180 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response to at least **90 days** with at least **one preferred** long-acting beta agonist **AND one preferred** long-acting muscarinic antagonist-containing inhalers
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Roflumilast (Daliresp)

Additional Roflumilast (Daliresp) Criteria

- Must be used in addition to a long-acting beta agonist AND a long-acting muscarinic antagonist-containing inhalers 

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment, adherence to maintenance inhaler per pharmacy claims, and ongoing safety monitoring

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=100){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=32){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
